Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
-
2081
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2082
-
2083
-
2084
-
2085
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2086
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2087
-
2088
-
2089
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2090
-
2091
-
2092
-
2093
-
2094
-
2095
-
2096
-
2097
-
2098
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: -
2099
-
2100